報價延遲最少15分鐘:2025/07/03 03:49 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.16/--
|
|
企業價值
15.73M
|
| 資產負債 |
|
每股賬面淨值
0.19
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/03 03:49 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. |